Zacks Research Issues Pessimistic Outlook for BAX Earnings

Baxter International Inc. (NYSE:BAX) – Equities research analysts at Zacks Research cut their Q1 2025 earnings per share estimates for Baxter International in a report released on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings of $0.49 per share for the quarter, down from their prior estimate of $0.50. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.66 EPS, Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.73 EPS, FY2026 earnings at $2.63 EPS and FY2027 earnings at $2.82 EPS.

Other research analysts also recently issued reports about the company. The Goldman Sachs Group began coverage on Baxter International in a report on Wednesday, February 26th. They issued a “buy” rating and a $42.00 target price on the stock. Argus upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Citigroup dropped their target price on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Barclays upped their price objective on shares of Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a research report on Monday, March 10th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $38.56.

Baxter International Stock Up 0.7 %

Shares of BAX opened at $34.85 on Monday. The company has a market capitalization of $17.83 billion, a P/E ratio of -27.22, a PEG ratio of 0.93 and a beta of 0.60. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.43 and a quick ratio of 1.09. Baxter International has a one year low of $28.34 and a one year high of $43.99. The business’s 50 day simple moving average is $32.57 and its 200-day simple moving average is $33.93.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. The company had revenue of $2.75 billion for the quarter, compared to the consensus estimate of $2.67 billion. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%.

Institutional Investors Weigh In On Baxter International

Hedge funds have recently bought and sold shares of the company. CoreFirst Bank & Trust acquired a new stake in Baxter International in the 4th quarter valued at about $26,000. Riverview Trust Co lifted its stake in Baxter International by 5,488.2% in the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 933 shares during the last quarter. LRI Investments LLC lifted its stake in Baxter International by 60.8% in the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 590 shares during the last quarter. CKW Financial Group lifted its stake in Baxter International by 100.0% in the 3rd quarter. CKW Financial Group now owns 2,200 shares of the medical instruments supplier’s stock valued at $81,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Bruce G. Allen Investments LLC lifted its stake in Baxter International by 247.3% in the 4th quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock valued at $76,000 after purchasing an additional 1,867 shares during the last quarter. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be paid a $0.17 dividend. The ex-dividend date is Friday, February 28th. This represents a $0.68 annualized dividend and a yield of 1.95%. Baxter International’s dividend payout ratio (DPR) is currently -53.13%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.